Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

Trial Details

NCT ID
NCT06108232
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Obinutuzumab
  • CC-99282
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients must meet the following criteria for study entry:
  • Histologically diagnosed follicular lymphoma grade 1-3a
  • Have no prior systemic treatment for lymphoma
  • Stage II, III or IV disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →